Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

ater convenience to patients versus the traditional IV method due to its less invasive administration route and quicker administration time (5 minutes versus 30 – 90 minutes).  
  • Roche reiterated their intent to file the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the EMA this year for the treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma.
  • Announced positive data with ViroPharma regarding a Phase 2 SC trial of Cinryze® (C1 esterase inhibitor [human]) in combination with rHuPH20, in patients with hereditary angioedema. Presented at the American Academy of Allergy Asthma & Immunology, the study demonstrated that SC co-administration of Cinryze with rHuPH20 was well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations.
  • Updated the Hylenex® recombinant (hyaluronidase human injection) label to include instructions for pre-administration of the enzyme in advance of other injected or subcutaneously infused drugs, and information from non-clinical studies that provide further data on the safety profile of Hylenex.
  • First Quarter 2012 Financial ResultsThe net loss for the first quarter of 2012 was $15.1 million, or $0.14 per share, compared with a net loss for the first quarter of 2011 of $9.6 million, or $0.10 per share.

  • Revenues for the first quarter of 2012 were $7.4 million, compared to $7.5 million for the first quarter of 2011. Revenues in the first quarter of 2012 primarily consisted of a milestone payment from Roche of $4 million and research and development reimbursements from partners.
  • Research and development expenses for the first quarter of 2012 were $15.9 million, compared with $13.8 million for the first quarter of 2011, primarily due to an increase in manufacturing activities and compensation costs, partially offset by a decrease in clinical trial act
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 2014  A Boston Scientific Corporation (NYSE: ... removability and preliminary long term stricture resolution of ... August issue of the peer-reviewed journal, Gastroenterology. ... being conducted in 11 countries and five continents, ... stents (FCSEMS) after extended indwell (i.e., up to ...
    (Date:8/29/2014)... 29, 2014 Medina Medical announced today that ... of the Board of Directors on August 18, 2014. ... and commercialization experience, including over a decade of direct ... as a Partner of the medical device incubator The ... two Foundry start-ups. Mr. Engelson previously served as the ...
    (Date:8/29/2014)... JORDAN, Utah , Aug. 29, 2014  BC ... Solutions, has acquired Polaris Medical Imaging, a leader in ... scanners. This strategic acquisition allows BC Technical to continue ... capabilities, specifically within MR and CT modalities. ... cost service," said Mark Alvarez , president and ...
    Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2BC Technical Acquires Polaris Medical Imaging 2
    ... Sept. 7 Symmetry Medical Inc. (NYSE: ... the global orthopedic device industry and other medical markets, ... and Chief Financial Officer, is scheduled to present at ... at the Stifel Nicolaus 2010 Healthcare Conference in Boston, ...
    ... MORRISTOWN, N.J., Sept. 7 Watson Pharmaceuticals, Inc. (NYSE: ... Watson Laboratories, Inc., has received approval from the United ... New Drug Application (ANDA) for Zarah™ (drospirenone and ethinyl ... Bayer,s Yasmin ® . Watson has begun shipping the ...
    Cached Medicine Technology:Symmetry Medical to Present at Two Upcoming Conferences 2Watson's Generic Yasmin® Receives FDA Approval 2
    (Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
    (Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
    (Date:8/30/2014)... "I had a handicapped friend who could ... an inventor from Wetumpka, Ala. "In order to help her ... shore, I came up with a way for her to ... prototype for the patent-pending Deezers to allow crutches to be ... use crutches, walkers, or canes at the beach. The device ...
    (Date:8/30/2014)... In today’s world, a good night’s sleep has ... and sleep apnea (a medical problem where the airway ... their bed partners of the rest they need to ... population snores and 20 million people in the United ... have been diagnosed and treated; and of those treated, ...
    (Date:8/30/2014)... 2014 The new review published by Daily ... by Karen Brimeyer, who wanted to make her guide accessible ... guide is now easy to find in the form of ... guide, the author of the new method shares all her ... Gossip writes in its review that the leaky gut syndrome ...
    Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
    ... ... Chief Executive ... Barr Laboratories, Inc., -- In this newly created ... and development, regulatory affairs, operations, quality, and sales and ...
    ... DENVER, March 28 Long-chain (seafood) omega-3,polyunsaturated fatty ... heart,brain and eye health, according to recent research ... PUFA Newsletter electronic publications.,Groundbreaking studies also show that ... dry eye syndrome., The effect of fish ...
    ... delivery more likely if either parent was born that way, ... one or both parents were born bottom first or feet ... twice as likely to be born the same way, Norwegian ... about one in 20 is born bottom first. Breech deliveries ...
    ... people and their families living with ... all types of ... hit television series "Heroes" and father of an 11-year-old son with,epilepsy ... to plan community awareness activities that will empower other,people living with ...
    ... 27 SEIU Spokesperson,Andrew McDonald said:, ... UHW-W leaders should focus on,helping 70,000 ... year. UHW-W members,deserve better than to ... by a distracted,UHW-W leadership.", For ...
    ... On March 25, 2008, The Honorable Dan,A. Polster, ... Liability Multi-District Litigation in the Northern District,of Ohio, ... Steering,Committee. One of these lawyers is Peter Burg ... Polster, and is responsible for conducting,pre-trial proceedings on ...
    Cached Medicine News:Health News:Barr Pharmaceuticals, Inc. Executive Bios 2Health News:Barr Pharmaceuticals, Inc. Executive Bios 3Health News:Barr Pharmaceuticals, Inc. Executive Bios 4Health News:Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes 2Health News:Breech Birth May Be Determined by Genes 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: